Short answer
GLP-1 research peptides are compounds that activate the GLP-1 receptor pathway. The category includes mono-agonists such as semaglutide, dual GIP/GLP-1 agonists such as tirzepatide, and triple agonists such as retatrutide. Labs use them to study incretin and metabolic signaling. This guide covers the pathway, the compound classes, and what to verify before ordering research-grade material.
What is the GLP-1 pathway?
GLP-1 (glucagon-like peptide-1) is a natural incretin hormone released from gut endocrine cells after a meal. It binds the GLP-1 receptor, a class B G-protein-coupled receptor expressed on pancreatic beta cells, alpha cells, the gut, and several brain regions, where it influences insulin secretion, glucagon secretion, gastric emptying, and appetite signaling. Because of this distributed biology, GLP-1 receptor agonism is one of the most active areas in metabolic research, and it forms the basis of a large and well-documented class of compounds [1].
The incretin field has progressed through successive generations of receptor complexity. The earliest compounds activate only the GLP-1 receptor. Newer compounds add activity at the GIP receptor (the receptor for the second major incretin hormone) and, most recently, at the glucagon receptor. Understanding this progression is essential for choosing the right compound for a given experiment.
The three main types
| Type | Example compounds | Receptor targets | Research focus |
|---|---|---|---|
| GLP-1 mono-agonists | Semaglutide, liraglutide | GLP-1 receptor | GLP-1 receptor signaling studies |
| Dual GIP/GLP-1 agonists | Tirzepatide | GIP + GLP-1 receptors | Combined incretin pathway research |
| Triple GIP/GLP-1/glucagon agonists | Retatrutide | GIP + GLP-1 + glucagon receptors | Multi-receptor metabolic research |
Dual and triple agonists are newer research tools that combine multiple receptor activities in a single molecule. Their value in the laboratory is that they enable experiments on how receptor combinations change signaling outcomes, without the confounding variables of mixing separate peptides [2]. Each class has a substantial research record, and each is catalogued in the GLP-1 & metabolic research category.
Mono-agonists: the GLP-1 reference class
The GLP-1 mono-agonists are the best-characterized members of the family. Semaglutide is the archetype: a GLP-1 analog engineered with an amino-acid substitution that blocks DPP-4 degradation and a C18 fatty-acid chain that binds albumin, extending its half-life to roughly one week. Its clinical pharmacology is documented in the STEP trial program, a series of phase 3 studies published in the New England Journal of Medicine [3].
For the laboratory, a mono-agonist serves as the reference GLP-1 receptor agonist. Any assay designed to test a novel incretin compound should be benchmarked against a mono-agonist to isolate the contribution of the added receptor activity. See our semaglutide research peptide guide for a full profile.
Dual agonists: adding the GIP receptor
The dual GIP/GLP-1 agonists add activity at the GIP receptor, which is expressed on beta cells and adipose tissue and is less completely characterized than the GLP-1 receptor. Tirzepatide is the reference compound of this class; its SURMOUNT-1 phase 3 trial, also published in the New England Journal of Medicine, randomized more than 2,500 adults and reported dose-dependent reductions in body weight over 72 weeks [4].
A recurring research question is how much of a dual agonist's overall pharmacology is attributable to the GIP arm versus the GLP-1 arm. Because the compound is a single molecule, this cannot be answered by inspection; researchers use selective antagonists, knockout models, and comparisons against mono-agonists to infer the contribution of each pathway. See our tirzepatide research peptide guide.
Triple agonists: the multi-receptor frontier
The triple agonists add the glucagon receptor, which is concentrated in the liver where it drives glucose output and fatty-acid oxidation. Retatrutide is the archetype, engaging GIP, GLP-1, and glucagon receptors in one molecule. Its phase 2 program includes a Lancet study in type 2 diabetes and a New England Journal of Medicine study in obesity, and a separate Nature Medicine trial examined its effects on liver fat in metabolic dysfunction-associated steatotic liver disease [5].
The glucagon arm is mechanistically the most novel addition, and the interaction between hepatic glucagon signaling and the incretin pathways is an active frontier of metabolic research. See our retatrutide research peptide guide.
What labs actually study
Common experimental themes with GLP-1 research peptides include:
The choice of compound depends on the question. A GLP-1-only question calls for a mono-agonist; a question about receptor interaction calls for a dual or triple agonist; a question about hepatic signaling may call for the triple class.
What to check before ordering
The analytical verification is especially important for this class because the compounds are large and heavily modified. A mass mismatch on a fatty-acylated peptide indicates a synthesis error that would invalidate the receptor pharmacology.
Reconstitution and handling considerations
Because the GLP-1 peptide family is large and heavily modified, handling practices deserve specific attention. Most compounds in the class are lyophilized powders intended to be reconstituted in the laboratory with a specified solvent. The reconstitution solvent, the temperature, and the handling of the lyophilized cake all affect the stability of the final solution, and the standard practice is to aliquot reconstituted material into single-use volumes to avoid repeated freeze-thaw cycles.
Two class-specific points are worth noting. First, the fatty-acid modification carried by many of these compounds is designed for albumin binding; this is a pharmacokinetic feature of the molecule and does not change how the lyophilized powder should be handled in the lab. Second, because the peptides are long and structurally elaborate, they are more prone to aggregation and degradation than short peptides, so prompt aliquoting and cold, dark storage matter more, not less. See our peptide storage guide and reconstitution protocol for the full detail.
Sourcing and regulatory context
The GLP-1 research peptide market has grown rapidly, and with it the importance of careful sourcing. The compounds in this class are sold for laboratory research use only, and the regulatory and compliance context is unambiguous: material must be clearly labelled as research-use-only, shipped with batch-specific documentation, and used exclusively in in-vitro research or approved animal models. Buyers should verify RUO labelling, batch traceability, and the analytical record before committing to a supplier.
It is also worth noting that the popularity of this class has attracted low-quality suppliers who may sell unmodified GLP-1, mis-synthesized peptides, or material without any meaningful analytical documentation. The checks in this guide - identity, purity, mass spectrometry, batch COA, lyophilized form - are not optional extras for this category; they are the minimum bar. Our supplier red flags guide covers the warning signs in detail, and the custom synthesis guide explains what to expect when commissioning material.
Building a comparative compound panel
Because the incretin field is organized around receptor complexity, many laboratories build a small panel of reference compounds rather than working with a single peptide. A typical panel covers the three tiers: a GLP-1 mono-agonist (semaglutide), a dual GIP/GLP-1 agonist (tirzepatide), and a triple GIP/GLP-1/glucagon agonist (retatrutide). With all three in hand, an investigator can run a receptor-activation or signaling assay across the full complexity spectrum in a single experimental series, and the differences between the three profiles become the data.
When building such a panel, keep the sourcing consistent: all three compounds should come with the same standard of analytical documentation so that differences between them can be attributed to pharmacology rather than to variable material quality. The same HPLC-purity, mass-spectrometry-identity, and batch-COA checks apply to each. This is where a single supplier with uniform quality control across the class simplifies the workflow, because the panel can be sourced with identical documentation standards and comparable batch-to-batch consistency across all three tiers of the receptor-complexity spectrum.
Common questions from labs
Do I need a special storage setup?
Most lyophilized peptides store fine at refrigerator or freezer temperatures, sealed and away from light. See our peptide storage guide for details.
Can I request the exact specification I need?
Yes - many suppliers offer custom synthesis for specific sequences and quantities. See our custom synthesis guide.
How do I verify quality after delivery?
Use the supplier's batch verification portal. PEPMAKE's COA lookup is on the quality page.
FAQ
What are GLP-1 research peptides?
Compounds that activate the GLP-1 receptor pathway, used in metabolic research.
What is the difference between mono, dual and triple agonists?
The number of receptor pathways a single molecule targets: GLP-1 only, GLP-1 + GIP, or GLP-1 + GIP + glucagon.
Are they for human use?
No, laboratory research use only.
What should I check before buying?
Batch-specific COA, HPLC purity, MS identity and RUO labeling.